We herein described a case of CML-myeloid BP with a long history of PV with JAK2 V617 F refractory to induction chemotherapy with TKIs, including dasatinib, nilotinib and bosutinib, which responded well to asciminib combined with ropegIFNα2b. This evidence concerns the gene JAK2 and acquired polycythemia vera.